目的:探讨中医药干预对慢性心力衰竭合并心房颤动患者近期心功能和远期预后的影响。方法:采用队列研究设计、倾向评分匹配(PSM)进行精确比较。使用医院病案管理系统提取患者信息、随访药物使用和终点事件发生情况。比较暴露组与非暴露...目的:探讨中医药干预对慢性心力衰竭合并心房颤动患者近期心功能和远期预后的影响。方法:采用队列研究设计、倾向评分匹配(PSM)进行精确比较。使用医院病案管理系统提取患者信息、随访药物使用和终点事件发生情况。比较暴露组与非暴露组治疗前后NYHA心功能分级、LVEF、NT-proBNP改变和心衰再入院、心源性死亡发生情况。Kaplan-Meier生存分析、Cox生存分析探讨中医药干预与心衰再入院、心源性死亡的关系。结果:共检索到符合要求患者959例,成功随访842例,倾向评分匹配成功771例。治疗前后暴露组和非暴露组NYHA分级、LVEF、NT-proBNP改善值分别为0.70 vs 0.58、8.15%vs 6.74%、1038pg/mL vs 942pg/mL。PSM前和PSM后,暴露组心衰再入院率及心源性死亡率均显著低于非暴露组(P<0.01)。Kaplan-Meier生存分析表明,暴露组在相同随访时间点心衰再入院率和心源性死亡率低于非暴露组,暴露组生存率显著高于非暴露组(P<0.01)。Cox生存分析表明,中医药干预是心衰再入院和心源性死亡的保护因素。结论:西医常规疗法联合中医药干预能够更好地改善慢性心力衰竭合并心房颤动患者的心功能,降低心衰再入院率和心源性死亡率,改善近期和远期预后。展开更多
目的:探讨中医药干预心肌梗死合并高脂血症患者的真实世界疗效。方法:采用队列研究设计。住院期间以应用中药注射剂≥7d为暴露组。随访期间以应用中成药和中药汤剂≥28d为暴露组。收集患者住院和随访期间的一般资料(姓名、年龄、性别和...目的:探讨中医药干预心肌梗死合并高脂血症患者的真实世界疗效。方法:采用队列研究设计。住院期间以应用中药注射剂≥7d为暴露组。随访期间以应用中成药和中药汤剂≥28d为暴露组。收集患者住院和随访期间的一般资料(姓名、年龄、性别和合并症等)、中药使用情况和终点事件发生情况。运用多元L o g i s t i c回归探讨中医药干预与心肌梗死合并高脂血症患者终点事件发生的相关性。结果:共纳入707例急性心肌梗死合并高脂血症患者,完成随访538例。住院期间中医药干预(OR=2.641,95%CI=1.757-3.972)、年龄(OR=1.061,95%CI=1.027-1.097)、抗心肌缺血治疗(OR=2.928,95%CI=1.300-6.595)是心源性死亡的相关因素,中医药干预(OR=2.051,95%CI=1.323-3.180)、年龄(OR=1.052,95%CI=1.016-1.089)、抗心肌缺血治疗(OR=2.621,95%CI=1.102-6.235)是心源性休克的相关因素,中医药干预(OR=1.732,95%CI=1.123-2.669)、血脂异常(OR=2.125,95%CI=1.115-4.049)是严重心律失常的相关因素。随访期间中医药干预(OR=1.341,95%CI=1.074-1.675)、年龄(OR=1.051,95%CI=1.022-1.081)、糖尿病(OR=2.769,95%CI=1.618-4.738)、抗栓治疗(OR=0.256,95%CI=0.117-0.560)是心源性死亡的相关因素,中医药干预(OR=1.575,95%CI=1.224-2.027)、年龄(OR=1.037,95%CI=1.007-1.068)、性别(OR=0.373,95%CI=0.193-0.721)、抗栓治疗(OR=0.346,95%CI=0.136-0.882)是再梗死和脑卒中复合终点事件的相关因素。结论:中医药干预能够减少心肌梗死合并高脂血症患者住院期间心源性死亡、心源性休克、严重心律失常和随访期间心源性死亡、再梗死和脑卒中复合终点事件的发生。展开更多
Objective:To explore the effect of Shenmai Injection(SMI)on the long-term prognosis of patients with chronic heart failure(CHF).Methods:The Hospital Information System was used to extract data of CHF patients,and the ...Objective:To explore the effect of Shenmai Injection(SMI)on the long-term prognosis of patients with chronic heart failure(CHF).Methods:The Hospital Information System was used to extract data of CHF patients,and the retrospective cohort study was conducted for analysis.In non-exposed group,standardized Western medicine treatment and Chinese patent medicine or decoction were applied without combination of SMI while in the exposed group,SMI were applied for more than 7 days.Evaluation indicators are followed with New York Heart Association functional classification(NYHA classification),left ventricular ejection fraction(LVEF),N-terminal brain natriuretic peptide precursor(NT-ProBNP),cardiogenic death and heart failure(HF)readmission.Statistical analysis includes Kaplan-Meier analysis and Cox regression which are used to explore the relationship between SMI and outcome events.Results:A total of 1,211 eligible CHF patients were involved and finally 1,047 patients were followed up successfully.After treatment,the cases of NYHA classification decline in the exposed and non-exposed groups accounted for 64.30%and 43.45%,respectively;the improvement values of LVEF were 8.89%and 7.91%,respectively;the improvement values of NT-ProBNP were 909 pg/mL and 735 pg/mL,respectively.After exposure on SMI,the rates of cardiogenic death and HF readmission reduced from 15.43%to 10.18%and 38.93%to 32.37%.According to Kaplan-Meier analysis,the log-rank P value of SMI and cardiogenic death was 0.014,while the counterpart of SMI and HF readmission was 0.025.Cox regression analysis indicated that for cardiogenic death,age,cardiomyopathy,diabetes,and NYHA classification were risk factors whileβ-blockers,aldosterone receptor antagonists,Chinese patent medicine/decoction and SMI were protective factors.Likewise,for HF readmission,age,cardiomyopathy,and NYHA classification were risk factors while SMI was a protective factor.Conclusion:Combination with SMI on the standardized Western medicine treatment can effectively reduce cardiogenic mortality and readmission rate in CHF patients,and thereby improve the long-term prognosis.展开更多
文摘目的:探讨中医药干预对慢性心力衰竭合并心房颤动患者近期心功能和远期预后的影响。方法:采用队列研究设计、倾向评分匹配(PSM)进行精确比较。使用医院病案管理系统提取患者信息、随访药物使用和终点事件发生情况。比较暴露组与非暴露组治疗前后NYHA心功能分级、LVEF、NT-proBNP改变和心衰再入院、心源性死亡发生情况。Kaplan-Meier生存分析、Cox生存分析探讨中医药干预与心衰再入院、心源性死亡的关系。结果:共检索到符合要求患者959例,成功随访842例,倾向评分匹配成功771例。治疗前后暴露组和非暴露组NYHA分级、LVEF、NT-proBNP改善值分别为0.70 vs 0.58、8.15%vs 6.74%、1038pg/mL vs 942pg/mL。PSM前和PSM后,暴露组心衰再入院率及心源性死亡率均显著低于非暴露组(P<0.01)。Kaplan-Meier生存分析表明,暴露组在相同随访时间点心衰再入院率和心源性死亡率低于非暴露组,暴露组生存率显著高于非暴露组(P<0.01)。Cox生存分析表明,中医药干预是心衰再入院和心源性死亡的保护因素。结论:西医常规疗法联合中医药干预能够更好地改善慢性心力衰竭合并心房颤动患者的心功能,降低心衰再入院率和心源性死亡率,改善近期和远期预后。
文摘目的:探讨中医药干预心肌梗死合并高脂血症患者的真实世界疗效。方法:采用队列研究设计。住院期间以应用中药注射剂≥7d为暴露组。随访期间以应用中成药和中药汤剂≥28d为暴露组。收集患者住院和随访期间的一般资料(姓名、年龄、性别和合并症等)、中药使用情况和终点事件发生情况。运用多元L o g i s t i c回归探讨中医药干预与心肌梗死合并高脂血症患者终点事件发生的相关性。结果:共纳入707例急性心肌梗死合并高脂血症患者,完成随访538例。住院期间中医药干预(OR=2.641,95%CI=1.757-3.972)、年龄(OR=1.061,95%CI=1.027-1.097)、抗心肌缺血治疗(OR=2.928,95%CI=1.300-6.595)是心源性死亡的相关因素,中医药干预(OR=2.051,95%CI=1.323-3.180)、年龄(OR=1.052,95%CI=1.016-1.089)、抗心肌缺血治疗(OR=2.621,95%CI=1.102-6.235)是心源性休克的相关因素,中医药干预(OR=1.732,95%CI=1.123-2.669)、血脂异常(OR=2.125,95%CI=1.115-4.049)是严重心律失常的相关因素。随访期间中医药干预(OR=1.341,95%CI=1.074-1.675)、年龄(OR=1.051,95%CI=1.022-1.081)、糖尿病(OR=2.769,95%CI=1.618-4.738)、抗栓治疗(OR=0.256,95%CI=0.117-0.560)是心源性死亡的相关因素,中医药干预(OR=1.575,95%CI=1.224-2.027)、年龄(OR=1.037,95%CI=1.007-1.068)、性别(OR=0.373,95%CI=0.193-0.721)、抗栓治疗(OR=0.346,95%CI=0.136-0.882)是再梗死和脑卒中复合终点事件的相关因素。结论:中医药干预能够减少心肌梗死合并高脂血症患者住院期间心源性死亡、心源性休克、严重心律失常和随访期间心源性死亡、再梗死和脑卒中复合终点事件的发生。
基金Supported by National Key R&D Program of China(No.2019YFC1710400 and No.2019YFC1710401)National Natural Science Foundation of China(No.81774047)。
文摘Objective:To explore the effect of Shenmai Injection(SMI)on the long-term prognosis of patients with chronic heart failure(CHF).Methods:The Hospital Information System was used to extract data of CHF patients,and the retrospective cohort study was conducted for analysis.In non-exposed group,standardized Western medicine treatment and Chinese patent medicine or decoction were applied without combination of SMI while in the exposed group,SMI were applied for more than 7 days.Evaluation indicators are followed with New York Heart Association functional classification(NYHA classification),left ventricular ejection fraction(LVEF),N-terminal brain natriuretic peptide precursor(NT-ProBNP),cardiogenic death and heart failure(HF)readmission.Statistical analysis includes Kaplan-Meier analysis and Cox regression which are used to explore the relationship between SMI and outcome events.Results:A total of 1,211 eligible CHF patients were involved and finally 1,047 patients were followed up successfully.After treatment,the cases of NYHA classification decline in the exposed and non-exposed groups accounted for 64.30%and 43.45%,respectively;the improvement values of LVEF were 8.89%and 7.91%,respectively;the improvement values of NT-ProBNP were 909 pg/mL and 735 pg/mL,respectively.After exposure on SMI,the rates of cardiogenic death and HF readmission reduced from 15.43%to 10.18%and 38.93%to 32.37%.According to Kaplan-Meier analysis,the log-rank P value of SMI and cardiogenic death was 0.014,while the counterpart of SMI and HF readmission was 0.025.Cox regression analysis indicated that for cardiogenic death,age,cardiomyopathy,diabetes,and NYHA classification were risk factors whileβ-blockers,aldosterone receptor antagonists,Chinese patent medicine/decoction and SMI were protective factors.Likewise,for HF readmission,age,cardiomyopathy,and NYHA classification were risk factors while SMI was a protective factor.Conclusion:Combination with SMI on the standardized Western medicine treatment can effectively reduce cardiogenic mortality and readmission rate in CHF patients,and thereby improve the long-term prognosis.
